Terns Pharmaceuticals Inc

-0.52 (-7.29%)
Products, Regulatory

Terns Reports Positive Top-Line Results From Phase 1 Proof Of Concept Clinical Trial Of Thr-Β Agonist Tern-501

Published: 11/09/2021 22:25 GMT
Terns Pharmaceuticals Inc (TERN) - Terns Reports Positive Top-line Results From Phase 1 Proof of Concept Clinical Trial of Thr-Β Agonist Tern-501.
Terns Pharmaceuticals - Tern-501 Demonstrated Significant Effects on Key Pharmacodynamic Marker of Thr-Β Engagement Linked to Nash Histologic Efficacy.
Terns Pharmaceuticals Inc - Tern-501 Was Generally Safe and Well-tolerated With Predictable Pharmacokinetic Profile With Low Variability.
Terns Pharmaceuticals Inc - Terns Plans to Initiate First Fxr/thr-Β Agonist Combination Trial in Nash in 1h 2022.